08.03.2021

New Meta-Analysis Confirms Efficacy of Cerebrolysin®

Worldwide, TBI is a leading cause of injury-related death and disability, with a devastating impact on patients and their families! Moderate-to-severe TBI can result in mortality rates as high as 30-40%. Survivors experience a substantial burden of physical, psychiatric, emotional and cognitive disabilities which disrupt the lives of individuals and their families. This results in major costs for individuals and families, and for society as a whole.

The meta-analysis of the CAPTAIN trials confirms the safety and efficacy of Cerebrolysin® after moderate-severe TBI, opening a new horizon in acute neuroprotection and for longterm neurorecovery in this field.

It summarizes the results from both trials, evaluates the effects of Cerebrolysin® in moderate-severe traumatic brain injury.

The effective treatment after TBI - Cerebrolysin® - offers results in:

•    Acute neuroprotection
•    Early recovery
•    Better quality of life
•    Saved lives

The whole study of CAPTAIN Meta-Analysis please find here.